Reintroducing
COVID-19 toolkit
Connect with us
Research
Continually investing
in our pipeline

As times change, so do your treatment needs. Ortho Dermatologics wants to help you help your patients now and in the future.

Watch

Radhakrishnan (RK) Pillai, PhD Vice President,
Research and Development Ortho Dermatologics

Jonathan S. Weiss, MD, in practice in Georgia for 33 years

Investing in the Future

Join Radhakrishhnan (RK) Pillai, PhD,
Ortho Dermatologics' Head of
Dermatology Development, and
Dr. Jonathan Weiss, MD,
dermatologist and assistant
clinical professor, as they discuss
everything from formulation
to finished product
DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
ALTRENO® (tretinoin) Lotion, 0.05%
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
ARAZLO™ (tazarotene) Lotion, 0.045%
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
BRYHALI® (halobetasol propionate) Lotion, 0.01%
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
IDP-120   Acne
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
IDP-124   Atopic Dermatitis
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available
IDP-126   Acne
See Clinical Trial
Pre-Clinical Phase I Phase II Phase III NDA Filed FDA
Approval Available

Learn more about our philanthropic efforts
X
X
X